{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T11:41:11Z","timestamp":1778845271873,"version":"3.51.4"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Ladieu Family Melanoma Research Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The biological and clinical relevance of gene fusions in melanoma is unknown. Reports and preclinical data have suggested that tumor cells with specific rearrangements such as RAF1 gene fusions could be therapeutically targeted. To investigate the relevance of targeted therapy in patients with melanoma harboring RAF1 gene fusions, we reviewed records of 1268 melanoma patients with targeted sequencing data at the Dana-Farber Cancer Institute. We identified 9 cases and report here on their clinicopathologic characteristics. We describe the favorable outcome of 2 patients who received MEK inhibitor therapy, including 1 patient with a durable response. We coalesced our data with published reports of patients with RAF1 gene fusions who were treated with targeted therapy. We find that single-agent MEK inhibition has anti-tumor activity in melanoma patients harboring an RAF1 gene fusion, and we propose that patients with RAF1 gene fusions should be considered for single-agent MEK inhibitor therapy.<\/jats:p>","DOI":"10.1093\/oncolo\/oyae297","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T22:28:13Z","timestamp":1730932093000},"source":"Crossref","is-referenced-by-count":4,"title":["Targeting <i>RAF1<\/i> gene fusions with MEK inhibition in metastatic melanoma"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6697-3516","authenticated-orcid":false,"given":"Karam","family":"Khaddour","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute Department of Medical Oncology, , Boston, MA 02115 ,","place":["United States"]},{"name":"Melanoma Disease Center, Dana-Farber Cancer Institute , Boston, MA 02115 ,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA 02115 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rizwan","family":"Haq","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute Department of Medical Oncology, , Boston, MA 02115 ,","place":["United States"]},{"name":"Melanoma Disease Center, Dana-Farber Cancer Institute , Boston, MA 02115 ,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA 02115 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth I","family":"Buchbinder","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute Department of Medical Oncology, , Boston, MA 02115 ,","place":["United States"]},{"name":"Melanoma Disease Center, Dana-Farber Cancer Institute , Boston, MA 02115 ,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA 02115 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Liu","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute Department of Medical Oncology, , Boston, MA 02115 ,","place":["United States"]},{"name":"Melanoma Disease Center, Dana-Farber Cancer Institute , Boston, MA 02115 ,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA 02115 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P","family":"Manos","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute Department of Medical Oncology, , Boston, MA 02115 ,","place":["United States"]},{"name":"Melanoma Disease Center, Dana-Farber Cancer Institute , Boston, MA 02115 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick A","family":"Ott","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute Department of Medical Oncology, , Boston, MA 02115 ,","place":["United States"]},{"name":"Melanoma Disease Center, Dana-Farber Cancer Institute , Boston, MA 02115 ,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA 02115 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F Stephen","family":"Hodi","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute Department of Medical Oncology, , Boston, MA 02115 ,","place":["United States"]},{"name":"Melanoma Disease Center, Dana-Farber Cancer Institute , Boston, MA 02115 ,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA 02115 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6078-6506","authenticated-orcid":false,"given":"Megan L","family":"Insco","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute Department of Medical Oncology, , Boston, MA 02115 ,","place":["United States"]},{"name":"Melanoma Disease Center, Dana-Farber Cancer Institute , Boston, MA 02115 ,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA 02115 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"2025033004005646700_CIT0001","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrc2091","article-title":"The impact of translocations and gene fusions on cancer causation","volume":"7","author":"Mitelman","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"2025033004005646700_CIT0002","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41574-021-00470-9","article-title":"The importance of the RET gene in thyroid cancer and therapeutic implications","volume":"17","author":"Salvatore","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"2025033004005646700_CIT0003","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat Med"},{"key":"2025033004005646700_CIT0004","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1089\/thy.2017.0318","article-title":"Gene fusions in thyroid cancer","volume":"28","author":"Yakushina","year":"2018","journal-title":"Thyroid"},{"key":"2025033004005646700_CIT0005","doi-asserted-by":"crossref","first-page":"e13517","DOI":"10.1200\/JCO.2020.38.15_suppl.e13517","article-title":"Druggable fusion gene landscape in solid tumors","volume":"38","author":"Williams","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025033004005646700_CIT0006","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1038\/s41379-022-01138-z","article-title":"Identification of fusions with potential clinical significance in melanoma","volume":"35","author":"Moran","year":"2022","journal-title":"Mod Pathol"},{"key":"2025033004005646700_CIT0007","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/1078-0432.CCR-20-4189","article-title":"Therapeutic implications of detecting MAPK-activating alterations in cutaneous and unknown primary melanomas","volume":"27","author":"Shoushtari","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025033004005646700_CIT0008","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1038\/s41379-020-0510-7","article-title":"Melanomas with activating RAF1 fusions: clinical, histopathologic, and molecular profiles","volume":"33","author":"Williams","year":"2020","journal-title":"Mod Pathol"},{"key":"2025033004005646700_CIT0009","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1002\/ONCO.13519","article-title":"Targetable BRAF and RAF1 Alterations in advanced pediatric cancers","volume":"26","author":"Rankin","year":"2021","journal-title":"Oncologist"},{"key":"2025033004005646700_CIT0010","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"2025033004005646700_CIT0011","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"2025033004005646700_CIT0012","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5858\/arpa.2016-0527-OA","article-title":"Validation of oncopanel: a targeted next-generation sequencing assay for the detection of somatic variants in cancer","volume":"141","author":"Garcia","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"2025033004005646700_CIT0013","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1093\/nar\/gku1211","article-title":"BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers","volume":"43","author":"Abo","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2025033004005646700_CIT0014","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1172\/JCI123089","article-title":"Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion","volume":"129","author":"McEvoy","year":"2019","journal-title":"J Clin Invest"},{"key":"2025033004005646700_CIT0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00138","article-title":"Significant clinical response to a MEK inhibitor therapy in a patient with metastatic melanoma harboring an RAF1 fusion","volume":"2","author":"Kim","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"2025033004005646700_CIT0016","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejca.2021.02.001","article-title":"A case of multi-metastatic melanoma with RAF1 fusion: a surprising response to anti-MEK therapy","volume":"147","author":"Pacaud","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025033004005646700_CIT0017","doi-asserted-by":"crossref","first-page":"e256","DOI":"10.1111\/1346-8138.15849","article-title":"Clinical response to a MEK inhibitor in a patient with metastatic melanoma harboring an RAF1 gene rearrangement detected by cancer gene panel testing","volume":"48","author":"Nakama","year":"2021","journal-title":"J Dermatol"},{"key":"2025033004005646700_CIT0018","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/CMR.0000000000000882","article-title":"Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene","volume":"33","author":"Boileau","year":"2023","journal-title":"Melanoma Res"},{"key":"2025033004005646700_CIT0019","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1158\/2159-8290.CD-22-0603","article-title":"Comparative genomics provides etiologic and biological insight into melanoma subtypes","volume":"12","author":"Newell","year":"2022","journal-title":"Cancer Discov"},{"key":"2025033004005646700_CIT0020","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ccell.2015.08.001","article-title":"BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition","volume":"28","author":"Yao","year":"2015","journal-title":"Cancer Cell"},{"key":"2025033004005646700_CIT0021","doi-asserted-by":"crossref","first-page":"9214","DOI":"10.1073\/pnas.95.16.9214","article-title":"Autoregulation of the Raf-1 serine\/threonine kinase","volume":"95","author":"Cutler","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025033004005646700_CIT0022","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/WCO.0000000000000146","article-title":"BRAF alterations in brain tumours: molecular pathology and therapeutic opportunities","volume":"27","author":"Berghoff","year":"2014","journal-title":"Curr Opin Neurol"},{"key":"2025033004005646700_CIT0023","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.3390\/cancers13225847","article-title":"Melanoma targeted therapies beyond BRAF-mutant melanoma: potential druggable mutations and novel treatment approaches","volume":"13","author":"Khaddour","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025033004005646700_CIT0024","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1001\/jamaoncol.2020.4401","article-title":"Rationale for immune checkpoint inhibitors plus targeted therapy in metastatic melanoma: a review","volume":"6","author":"Dummer","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025033004005646700_CIT0025","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","article-title":"The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial","volume":"30","author":"Kilburn","year":"2024","journal-title":"Nat Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/3\/oyae297\/60456285\/oyae297.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/3\/oyae297\/60456285\/oyae297.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T19:32:19Z","timestamp":1743449539000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae297\/7879608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,10]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae297","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,11,6]]},"article-number":"oyae297"}}